Ulla Hedner
Overview
Explore the profile of Ulla Hedner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hedner U
Blood Rev
. 2015 Jun;
29 Suppl 1:S4-8.
PMID: 26073368
Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital haemophilia and inhibitors. The story of its development began in the 1970s, when FVIIa...
2.
Shapiro A, Hedner U
Ther Adv Drug Saf
. 2014 Aug;
2(5):213-25.
PMID: 25083214
In the past, patients with hemophilia and inhibitors have had less-than-optimal treatment and have experienced more orthopedic complications than patients without inhibitors. Bypassing agents offer the potential to close treatment...
3.
Lambert T, Auerswald G, Benson G, Hedner U, Jimenez-Yuste V, Ljung R, et al.
Thromb Res
. 2014 Mar;
133(6):967-71.
PMID: 24613700
Although effective therapies for haemophilia have been available for decades, the prevention and treatment of joint disease remain major clinical concerns for all haemophilia patients. Early identification of joint disease...
4.
Sen P, Clark C, Gopalakrishnan R, Hedner U, Esmon C, Pendurthi U, et al.
Thromb Haemost
. 2012 Feb;
107(5):951-61.
PMID: 22370814
Recent in vitro studies have shown that the zymogen and activated form of factor (F)VII bind to endothelial cell protein C receptor (EPCR). At present, there is no evidence that...
5.
Hedner U
Front Biosci (Elite Ed)
. 2011 Dec;
4(4):1210-23.
PMID: 22201947
Around 20 % of the patients with severe hemophilia develop inhibitory antibodies against the factor they lack. In these patients the administration of FVIII/FIX-concentrates are not hemostatically effective. Since FVIIa...
6.
Brophy D, Martin E, Barrett J, Nolte M, Kuhn J, Hedner U, et al.
Blood Coagul Fibrinolysis
. 2011 Jun;
22(6):541-6.
PMID: 21681082
In a previous pharmacokinetic/pharmacodynamic study in nonbleeding hemophilia patients, variability in laboratory response to recombinant factor VIIa (rFVIIa) 90 μg/kg was noted, and the patients were described as delayed or...
7.
Lopez-Vilchez I, Hedner U, Altisent C, Diaz-Ricart M, Escolar G, Galan A
Am J Pathol
. 2011 Jun;
178(6):2938-48.
PMID: 21641410
Clinical evidence accumulated from hemophilic patients during prophylaxis with recombinant activated factor VII (rFVIIa) suggests that the duration of the hemostatic action of rFVIIa exceeds its predicted plasma half-life. Mechanisms...
8.
Gray L, Hussey M, Larson B, Machlus K, Campbell R, Koch G, et al.
Thromb Res
. 2011 May;
128(6):570-6.
PMID: 21561645
Introduction: The bypassing agent recombinant factor VIIa (rFVIIa) is efficacious in treating bleeding in hemophilia patients with inhibitors. Efforts have focused on the rational engineering of rFVIIa variants with increased...
9.
Hedner U
Thromb Res
. 2010 Mar;
125 Suppl 1:S4-6.
PMID: 20188400
Hemophilia patients with inhibitors against FVIII/FIX present with a major challenge in the clinical practice. In the 1970s such patients were treated in association with emergency situations and essential surgery...
10.
He S, Ezban M, Bark N, Persson E, Hedner U
Thromb Haemost
. 2009 Oct;
102(4):790-2.
PMID: 19806268
No abstract available.